2.8
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for…
Drug-induced modification of DNA is called mutagenicity. If the mutations affect the tumor suppressor genes or proto-oncogenes, it can lead to carcinogenesis.
Carcinogenesis begins with tumor initiation. Here, a genotoxic carcinogen—called an initiator—mutates a gene to inhibit cellular apoptosis and promote proliferation.
This is followed by the tumor promotion step, where an epigenetic carcinogen —called a promoter—alters the cellular environment to promote the survival of pre-cancerous cells.
The IARC categorizes chemicals into four groups based on their carcinogenic potential.
The genotoxic potential of such carcinogens is assessed using in vitro and in vivo tests.
In vitro mutagenicity tests such as the Ames test, chromosome aberrations and sister chromatid exchange assays are rapid and inexpensive, but they can have some false results.
In vivo carcinogenicity tests involve chronic dosing in animals, followed by the detection of tumors. Although expensive and time-consuming, they are required to assess the risks to human health.
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between mutagenicity and carcinogenicity?
Mutagenicity refers to drug-induced modification of DNA, while carcinogenicity is the ability to induce cancer. Mutations affecting tumor suppressor genes or proto-oncogenes can lead to carcinogenesis. Not all mutations cause cancer, but those affecting genes regulating cell growth may result in cancer development through effects of chemicals overview.
Q2: How does carcinogenesis progress through tumor initiation and promotion?
Tumor initiation occurs when a genotoxic carcinogen called an initiator mutates a gene to inhibit cellular apoptosis and promote proliferation. Tumor promotion follows, where an epigenetic carcinogen called a promoter alters the cellular environment to promote survival of pre-cancerous cells, advancing cancer development.
Q3: How does the IARC classify carcinogenic chemicals?
The IARC categorizes chemicals into four groups based on carcinogenic potential. Group 1 includes known human carcinogens; Group 2A contains probably carcinogenic agents; Group 3 lacks sufficient data; and Group 4 includes agents with data supporting they are not likely carcinogens.
Q4: What are the advantages and limitations of in vitro mutagenicity tests?
In vitro tests like the Ames test, chromosome aberrations, and sister chromatid exchange assays are rapid and inexpensive screening tools. However, they have limited predictive value for carcinogenicity and can produce false results, requiring confirmation with more comprehensive in vivo testing.
Q5: Why are in vivo carcinogenicity tests necessary despite their drawbacks?
In vivo carcinogenicity tests involve chronic animal dosing followed by tumor detection. Although expensive and time-consuming, they are required to assess risks to human health and are mandated by regulatory authorities before licensing drugs for clinical use. These tests provide essential safety data.
Q6: How can reactive metabolites contribute to mutagenicity and carcinogenicity?
Reactive metabolites formed during drug oxidation can cause structural chromosomal abnormalities and DNA mutations. These metabolites may also modify cellular signaling pathways and the cellular environment, promoting survival and proliferation of pre-cancerous cells through non-DNA interactions and toxic reactions overview.
Q7: What substances are known to have mutagenic and carcinogenic potential?
Substances with mutagenic and carcinogenic potential include anticancer drugs, estrogens, tobacco, and radioisotopes. These agents can cause genetic defects and induce cancer through various mechanisms, making their assessment critical for drug safety, public health protection, and regulatory compliance in clinical practice.